Tesamorelin’s approval, recorded September 28, 2026, covers adults with HIV and lipodystrophy who have extra belly fat.
Using tesamorelin for a different purpose is called off-label use.
That term describes the purpose of treatment. It does not tell you whether a doctor is allowed to offer that treatment under your state’s rules. The approval record used here does not answer that question. Ask the doctor which rules apply where you are before deciding.
Read the research beside the approved use
Researchers have studied liver fat in people with HIV, but that is not an approved tesamorelin use.
The liver-fat studies were small, and their authors called for more study of long-term effects.
Ask whether the people in a study had the same condition you have. Ask what changed, how it was measured and how long the study lasted.
Ask for the missing part
Research on thinking and memory has given mixed results and has not made tesamorelin an approved treatment for memory or ageing.
A useful answer can include uncertainty. Ask the doctor to separate what has been measured from what is hoped for.
Read the source notes
Source-check dates: September 28, 2026.
- DailyMed: the tesamorelin (EGRIFTA WR) label
- PubMed: Stanley and colleagues on liver fat in people with HIV
- PubMed: Baker and colleagues on thinking and memory
- PubMed: Ellis and colleagues on thinking in people with HIV
Ask for confirmation of the current product, rules and costs before deciding on care.